Citius Oncology, Inc. CTOR Interest Paid, Excluding Capitalized Interest, Operating Activity

Interest Paid, Excluding Capitalized Interest, Operating Activity at other companies

CSXCSX

$217.5M+2.4%

General MotorsGM

$1.66B+7.2%

PNC Financial ServicesPNC

$2.52B-7.1%

Cadence Design SystemsCDNS

$57.23M+2.7%

ServiceNowNOW

$11M0.0%

3MMMM

$116.75M-7.5%

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s interest paid, excluding capitalized interest, operating activity?: Citius Oncology, Inc. (CTOR) reported interest paid, excluding capitalized interest, operating activity of $14.46K in Q4 2025.
How has Citius Oncology, Inc.'s interest paid, excluding capitalized interest, operating activity changed year-over-year?: Citius Oncology, Inc.'s interest paid, excluding capitalized interest, operating activity decreased by 69.1% year-over-year, from $46.85K to $14.46K.